Literature DB >> 22190237

Mapping the road forward in Alzheimer's disease.

David M Holtzman1, Alison Goate, Jeffrey Kelly, Reisa Sperling.   

Abstract

Alzheimer's disease (AD) is the most common cause of dementia and will lead to a worldwide public health crisis if it continues unchecked. Despite tremendous advances in our scientific understanding of AD, we still do not have effective ways to delay, prevent, or slow this disease. At the 2011 Abelson meeting, a diverse group of scientists discussed current challenges in the AD field and made recommendations in the areas of genetics, clinical trials, protein aggregation, and the cell biology of the nervous system. We hope these recommendations will boost research progress in AD and increase the likelihood of developing effective therapies in the near future.

Entities:  

Mesh:

Year:  2011        PMID: 22190237     DOI: 10.1126/scitranslmed.3003529

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  29 in total

1.  Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease.

Authors:  Ines Moreno-Gonzalez; Lisbell D Estrada; Elisabeth Sanchez-Mejias; Claudio Soto
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

Review 2.  Epigenetic regulation of memory by acetylation and methylation of chromatin: implications in neurological disorders, aging, and addiction.

Authors:  Nilkantha Sen
Journal:  Neuromolecular Med       Date:  2014-04-29       Impact factor: 3.843

3.  Autophagy Induction by Bexarotene Promotes Mitophagy in Presenilin 1 Familial Alzheimer's Disease iPSC-Derived Neural Stem Cells.

Authors:  Patricia Martín-Maestro; Andrew Sproul; Hector Martinez; Dominik Paquet; Meri Gerges; Scott Noggle; Anatoly A Starkov
Journal:  Mol Neurobiol       Date:  2019-06-16       Impact factor: 5.590

4.  Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.

Authors:  Rawan Tarawneh; Denise Head; Samantha Allison; Virginia Buckles; Anne M Fagan; Jack H Ladenson; John C Morris; David M Holtzman
Journal:  JAMA Neurol       Date:  2015-06       Impact factor: 18.302

Review 5.  The future of blood-based biomarkers for Alzheimer's disease.

Authors:  Kim Henriksen; Sid E O'Bryant; Harald Hampel; John Q Trojanowski; Thomas J Montine; Andreas Jeromin; Kaj Blennow; Anders Lönneborg; Tony Wyss-Coray; Holly Soares; Chantal Bazenet; Magnus Sjögren; William Hu; Simon Lovestone; Morten A Karsdal; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2013-07-11       Impact factor: 21.566

6.  Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.

Authors:  Oscar Harari; Carlos Cruchaga; John S K Kauwe; Benjamin J Ainscough; Kelly Bales; Eve H Pickering; Sarah Bertelsen; Anne M Fagan; David M Holtzman; John C Morris; Alison M Goate
Journal:  Biol Psychiatry       Date:  2014-01-19       Impact factor: 13.382

7.  Lithium rescues synaptic plasticity and memory in Down syndrome mice.

Authors:  Andrea Contestabile; Barbara Greco; Diego Ghezzi; Valter Tucci; Fabio Benfenati; Laura Gasparini
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

8.  β-arrestin 2 regulates Aβ generation and γ-secretase activity in Alzheimer's disease.

Authors:  Amantha Thathiah; Katrien Horré; An Snellinx; Elke Vandewyer; Yunhong Huang; Marta Ciesielska; Gerdien De Kloe; Sebastian Munck; Bart De Strooper
Journal:  Nat Med       Date:  2012-12-02       Impact factor: 53.440

9.  Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer's disease.

Authors:  Jay Rasmussen; Jasmin Mahler; Natalie Beschorner; Stephan A Kaeser; Lisa M Häsler; Frank Baumann; Sofie Nyström; Erik Portelius; Kaj Blennow; Tammaryn Lashley; Nick C Fox; Diego Sepulveda-Falla; Markus Glatzel; Adrian L Oblak; Bernardino Ghetti; K Peter R Nilsson; Per Hammarström; Matthias Staufenbiel; Lary C Walker; Mathias Jucker
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-20       Impact factor: 11.205

10.  Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.

Authors:  Sandra Sivilia; Luca Lorenzini; Alessandro Giuliani; Marco Gusciglio; Mercedes Fernandez; Vito Antonio Baldassarro; Chiara Mangano; Luca Ferraro; Vladimiro Pietrini; Maria Francesca Baroc; Arturo R Viscomi; Simone Ottonello; Gino Villetti; Bruno P Imbimbo; Laura Calzà; Luciana Giardino
Journal:  BMC Neurosci       Date:  2013-04-05       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.